Health
Roche's Early Obesity Drug Trial Results Boost Shares
Shares of Swiss drugmaker Roche increased by 4.7% after the company reported promising results from an early-stage trial of its obesity drug candidate, CT-388, developed by the recently acquired Carmot Therapeutics. The study showed that CT-388 led to an average weight loss of 18.8% over a 24-week period,